New Brunswick, N.J., November 15, 2022 – Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022. A total of 28 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma. Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
“We have a passionate team of world-class cancer specialists and researchers that is dedicated to transforming cancer care by developing novel strategies and medical advancements, including participation in close to 100 clinical trials throughout our system, all with the single goal of helping those facing a diagnosis of a blood cancer to live longer and live better,” said Matthew Matasar, MD, MS, Chief of Blood Disorders at Rutgers Cancer Institute and RWJBarnabas Health. “The remarkable breadth of our faculty’s contribution to their fields being presented at this year’s ASH Annual Meeting and Exposition affirms the strong foundation of clinical excellence, discovery and innovation that defines Rutgers Cancer Institute and RWJBarnabas Health as a leader in New Jersey, nationally, and globally in this new era of cancer treatment,” added Dr. Matasar, who oversees the Sections of Hematologic Malignancies, Transplant and Cell Therapy, and Benign Hematology, and is also Professor of Medicine at Rutgers Robert Wood Johnson Medical School.
Highlights of the accepted abstracts include the following oral presentations:
- Development and validation of the advanced-Stage Hodgkin Lymphoma International Prognostication Index (A-HIPI). This state-of-the-art model to predict progression-free and overall survival in adults with advanced stage classical Hodgkin lymphoma by five years uses comprehensive individual patient data from international clinical trials and large prospective registries that were standardized, normalized and harmonized as part of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium.
- Data from a multicenter phase 2 study evaluating the safety and efficacy of Polatuzumab vedotin (Pola) combined with rituximab, ifosfamide, carboplatin and etoposide (RICE) as second line treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in patients who relapse > 1 year after frontline treatment. Pola is an antibody-drug conjugate that is safe and effective when combined with chemotherapy in frontline and relapsed, transplant-ineligible DLBCL patients.
- Updated results, after a median follow up of 27 months, from a phase 2 study in which Mosunetuzumab (Mosun), a T-cell engaging bispecific monoclonal antibody (Bi-mAb), demonstrated a high rate of complete response with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who had received ≥2 prior therapies. Mosun, the first Bi-mAb approved for the treatment of patients with relapsed/refractory follicular lymphoma, is a fixed-duration treatment that can be administered in an outpatient setting.
The full list of presentations at this year’s ASH Annual Meeting and Exposition follows:
|
Oral Presentations |
||
|
Abstract and Session No. |
Title |
Presentation Date/Time |
|
Abstract 154 |
Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell TherapyClinically Relevant Abstract |
Saturday, December 10, 2022, at 12:45 PM CST |
|
Abstract 313 |
Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium |
Saturday, December 10, 2022, at 4:00 PM CST |
|
Abstract 442 |
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Sunday, December 11, 2022, at 10:15 AM CST |
|
Abstract 542 |
Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study |
Sunday, December 11, 2022, at 12:15 PM CST |
|
Abstract 610 |
Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study |
Sunday, December 11, 2022, at 5:15 PM CST |
|
(Session 613) |
Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) |
Sunday, December 11, 2022: 5:30 PM CST |
|
Abstract 730 |
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 |
Monday, December 12, 2022, at 11:15 AM CST |
|
(Session 616) |
Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial) |
Monday, December 12, 2022: 11:45 AM CST |
|
Abstract 1000 |
Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy |
Monday, December 12, 2022, at 5:15 PM CST |
|
Poster Presentations |
||
|
Abstract and Session No. |
Title |
Presentation |
|
Abstract 1510 |
Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331 |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 1520 |
Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 1576 |
Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 1628 |
Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 1669 |
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 1439 |
Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization |
Saturday, December 10, 2022, from 5:30-7:30 PM CST |
|
Abstract 2835 |
Identification of Genetic Subtypes in Follicular Lymphoma |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 2865 |
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 2882 |
Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 2885 |
FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 2897 |
Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 3584 |
COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 2699 |
Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) |
Sunday, December 11, 2022, from 6:00-8:00 PM CST |
|
Abstract 3702 |
Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
|
Abstract 3946 |
Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
|
Abstract 4183 |
Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
|
Abstract 4260 |
Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
|
Abstract 4555 |
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
|
Abstract 4922 |
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy |
Monday, December 12, 2022, from 6:00-8:00 PM CST |
About Rutgers Cancer Institute
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute in New Brunswick, Rutgers Cancer Institute at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute, call 848-932-8013 or visit www.cinj.org/giving.
##
For journalists – contact:
Krista Didzbalis
Media Relations Specialist
732 507 8307
krista.didzbalis@rutgers.edu
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)